Paper33682011
Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.
Moriyama J and 7 others. Surg Today, 2021. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer. Papers, record 33682011. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33682011
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| CA-19-9 Antigen | Major topic |
| Carcinoembryonic Antigen | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Stomach Neoplasms | Major topic |
| Female | |
| Gastrectomy | |
| Humans | |
| Lymph Node Excision | |
| Male | |
| Prognosis | |
| Retrospective Studies | |
| Survival Rate |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23564806 | Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer. | Anticancer Res | 2013 | https://conductscience.org/library/papers/23564806 | PubMed |
| 2 | 27097114 | Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27097114 | PubMed |
| 3 | 30923789 | Diagnostic impact of high serum midkine level in patients with gastric cancer. | Ann Gastroenterol Surg | 2019 | https://conductscience.org/library/papers/30923789 | PubMed |
| 4 | 23208313 | Investigation of the freely available easy-to-use software 'EZR' for medical statistics. | Bone Marrow Transplant | 2013 | https://conductscience.org/library/papers/23208313 | PubMed |
| 5 | 27147574 | Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection. | Oncotarget | 2016 | https://conductscience.org/library/papers/27147574 | PubMed |
| 6 | 32560392 | CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer. | J Clin Med | 2020 | https://conductscience.org/library/papers/32560392 | PubMed |
| 7 | 26576068 | Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis. | Dis Markers | 2015 | https://conductscience.org/library/papers/26576068 | PubMed |
| 8 | 29100454 | Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases. | Oncotarget | 2017 | https://conductscience.org/library/papers/29100454 | PubMed |
| 9 | 25854347 | Preoperative serum CEA and CA19-9 in gastric cancer--a single tertiary hospital study of 1,075 cases. | Asian Pac J Cancer Prev | 2015 | https://conductscience.org/library/papers/25854347 | PubMed |
| 10 | 29926189 | The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. | Surg Today | 2018 | https://conductscience.org/library/papers/29926189 | PubMed |
| 11 | 14520526 | The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. | Gastric Cancer | 2003 | https://conductscience.org/library/papers/14520526 | PubMed |
| 12 | 32458231 | Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. | Surg Today | 2020 | https://conductscience.org/library/papers/32458231 | PubMed |
| 13 | 27566604 | The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases. | Surg Today | 2017 | https://conductscience.org/library/papers/27566604 | PubMed |
| 14 | 30984347 | Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. | World J Gastrointest Oncol | 2019 | https://conductscience.org/library/papers/30984347 | PubMed |
| 15 | 32490341 | Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. | Ann Gastroenterol Surg | 2020 | https://conductscience.org/library/papers/32490341 | PubMed |
| 16 | 31820210 | Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA. | Int J Clin Oncol | 2020 | https://conductscience.org/library/papers/31820210 | PubMed |
| 17 | 29121872 | Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. | BMC Cancer | 2017 | https://conductscience.org/library/papers/29121872 | PubMed |
| 18 | 28441659 | Perioperative Serum Carcinoembryonic Antigen Levels Predict Recurrence and Survival of Patients with Pathological T2-4 Gastric Cancer Treated with Curative Gastrectomy. | Dig Surg | 2018 | https://conductscience.org/library/papers/28441659 | PubMed |
| 19 | 30574476 | Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing? | Gastrointest Tumors | 2018 | https://conductscience.org/library/papers/30574476 | PubMed |
| 20 | 25580353 | The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection. | J Gastric Cancer | 2014 | https://conductscience.org/library/papers/25580353 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42796292 | Intermediate-Term Oncological, Anastomotic and Nutritional Outcomes of the Sutureless L-Shaped Esophagojejunostomy with Endoscopic Assistance (SLEJ) in Totally Laparoscopic Total Gastrectomy: A Follow-Up Analysis of This Technique. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42796292 | PubMed |
| 42736302 | Value of preoperative peripheral blood inflammation markers in predicting prognosis after radical gastric cancer surgery. | Sci Rep | 2026 | https://conductscience.org/library/papers/42736302 | PubMed |
| 41906027 | CXCL12 and eotaxin are independent prognostic serum biomarkers in gastric cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/41906027 | PubMed |
| 41384977 | The prognostic value of serum lactate dehydrogenase levels in patients with carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-negative colorectal cancer. | Surg Today | 2026 | https://conductscience.org/library/papers/41384977 | PubMed |
| 40877868 | Novel surveillance protocol for gastric cancer based on CEA: a high-volume multi-center study. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40877868 | PubMed |
| 40673317 | [High PRELID1 expression promotes epithelial-mesenchymal transition in gastric cancer cells and is associated with poor prognosis]. | Nan Fang Yi Ke Da Xue Xue Bao | 2025 | https://conductscience.org/library/papers/40673317 | PubMed |
| 40647250 | Nutritional and Biochemical Outcomes After Total Versus Subtotal Gastrectomy: Insights into Early Postoperative Prognosis. | Nutrients | 2025 | https://conductscience.org/library/papers/40647250 | PubMed |
| 40406247 | Clinical value of CA125, AFP, and CEA for combined diagnosis and assessment of gastric cancer prognosis. | Front Oncol | 2025 | https://conductscience.org/library/papers/40406247 | PubMed |
| 38884851 | PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38884851 | PubMed |
| 38835478 | Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine Learning for Recurrence of Bladder Cancer Patients. | Cancer Manag Res | 2024 | https://conductscience.org/library/papers/38835478 | PubMed |
| 38703060 | Human circular RNA hsa_circ_0000231 clinical diagnostic effectiveness as a new tumor marker in gastric cancer. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/38703060 | PubMed |
| 38444686 | Development and validation of serological dynamic risk score to predict outcome in gastric cancer with adjuvant chemotherapy: a multicentre, longitudinal, cohort study. | Front Oncol | 2024 | https://conductscience.org/library/papers/38444686 | PubMed |
| 38263014 | CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy. | BMC Surg | 2024 | https://conductscience.org/library/papers/38263014 | PubMed |
| 38166693 | Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38166693 | PubMed |
| 37839102 | Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models. | J Surg Res | 2024 | https://conductscience.org/library/papers/37839102 | PubMed |
| 37728233 | Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients. | Cancer Control | 2023 | https://conductscience.org/library/papers/37728233 | PubMed |
| 37658871 | Prognostic factor in patient with recurrent pancreatic adenocarcinoma. | Langenbecks Arch Surg | 2023 | https://conductscience.org/library/papers/37658871 | PubMed |
| 37569566 | Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569566 | PubMed |
| 37545214 | LncRNA ARAP1-AS1 contributes to lung adenocarcinoma development by targeting miR-8068 to upregulate CEACAM5. | Cancer Biomark | 2023 | https://conductscience.org/library/papers/37545214 | PubMed |
| 37256148 | Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression. | Front Immunol | 2023 | https://conductscience.org/library/papers/37256148 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CEACAM1 | 634 | PubTator's text mining | https://conductscience.org/library/genes/634 | NCBI Gene |
| CEACAM3 | 1084 | PubTator's text mining | https://conductscience.org/library/genes/1084 | NCBI Gene |
| CEACAM5 | 1048 | PubTator's text mining | https://conductscience.org/library/genes/1048 | NCBI Gene |
| GDF15 | 9518 | PubTator's text mining | https://conductscience.org/library/genes/9518 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33682011
GET https://conductscience.org/api/papers/v1/33682011/references?page=2